A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

NCT06024239 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Generalized Anxiety Disorder (GAD)
Bipolar Disorder (BPD)

Interventions

DRUG: ABBV-932
DRUG: Placebo for ABBV-932

Sponsor

AbbVie